Last reviewed · How we verify
Colistin Sodium Methanesulfonate
At a glance
| Generic name | Colistin Sodium Methanesulfonate |
|---|---|
| Also known as | Colistin |
| Sponsor | Chiang Mai University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2, PHASE3)
- Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis (PHASE2)
- Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial (NA)
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
- Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline (PHASE4)
- Comparing Tigecycline Vs. Colistimethate in CNS Infections
- Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection (PHASE4)
- Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colistin Sodium Methanesulfonate CI brief — competitive landscape report
- Colistin Sodium Methanesulfonate updates RSS · CI watch RSS
- Chiang Mai University portfolio CI